<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814409</url>
  </required_header>
  <id_info>
    <org_study_id>NorthGlasgowU</org_study_id>
    <nct_id>NCT02814409</nct_id>
  </id_info>
  <brief_title>Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis</brief_title>
  <acronym>ATTEST2</acronym>
  <official_title>Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NHS Greater Glasgow and Clyde</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principle research question is: in patients with acute ischaemic stroke eligible for
      intravenous (IV) thrombolysis, is tenecteplase superior in efficacy to alteplase, based on
      functional outcome as assessed by modified Rankin Scale distribution at day 90?
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>modified Rankin Scale</measure>
    <time_frame>Day 90 (+/- 7)</time_frame>
    <description>modified Rankin Scale (mRS) at day 90, determined by the Rankin Focused Assessment (RFA) method using centralised telephone interview, analysed by ordinal distribution (&quot;shift&quot;) analysis of the scores in intervention and control groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Full neurological recovery (modified Rankin Scale 0-1 versus 2-6).</measure>
    <time_frame>Day 90 (+/- 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Independent recovery (modified Rankin Scale score 0-2 versus 3-6).</measure>
    <time_frame>Day 90 (+/- 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early major neurological improvement of 8 or more points, or return to the National Institutes of Health Stroke Scale (NIHSS) total score of 0 or 1 at 24 hour(s).</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (EuroQol five dimensions questionnaire, EQ-5D)</measure>
    <time_frame>Day 90 (+/- 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index score</measure>
    <time_frame>Day 90 (+/- 7)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 90 (+/- 7)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Imaging scan up to 36 hours, combined with a neurological deterioration NIHSS≥4 points from baseline (or lowest NIHSS value baseline-24 h), or leading to death (Safe Implementation of Thrombolysis in Stroke-Monitoring study definition).</measure>
    <time_frame>36 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Symptomatic Intra-Cerebral Haemorrhage (SICH) by (European Cooperative Acute Stroke Study) ECASS-2 and ECASS-3 definitions.</measure>
    <time_frame>up to day 90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Parenchymal Haematoma type 2 (PH2) haemorrhage on post-treatment computerised tomography (CT) scan up to 36 hours after treatment.</measure>
    <time_frame>36 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Intracranial haemorrhage</measure>
    <time_frame>22-36 hours</time_frame>
    <description>Any intracranial haemorrhage on 22-36 hours computerised tomography (CT) scan</description>
  </other_outcome>
  <other_outcome>
    <measure>Significant extracranial haemorrhage (requirement for blood transfusion or drop in haemoglobin of ≥20mg/l in the 36h after treatment).</measure>
    <time_frame>36 hours</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1870</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Alteplase - standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alteplase 0.9 mg/kg with 10% of the total dose administered as an initial intravenous bolus and remaining 90% of the total dose administered as an intravenous infusion over 1 hour (maximum dose 90mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenecteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase</intervention_name>
    <arm_group_label>Alteplase - standard care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Tenecteplase</intervention_name>
    <arm_group_label>Tenecteplase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Eligible for intravenous thrombolysis.

          -  Male or non-pregnant female ≥18 years of age.

          -  &lt;4.5h after symptom onset.

          -  Consent of patient or legal representative.

          -  Independent prior to the stroke (estimated modified Rankin Scale 0-1).

        Exclusion criteria:

          -  Eligible for intravenous thrombolysis: Evidence of intracranial haemorrhage or
             significant non-stroke intracranial pathology likely to account for clinical
             presentation or represent a risk of intracerebral haemorrhage (eg Central Nervous
             System neoplasm) on pre-treatment computerised tomography (CT) scan; Stroke within the
             previous 14 days, thrombolytic therapy within the past 14 days, or hypodensity on
             pre-treatment computerised tomography (CT) scan consistent with recent cerebral
             ischaemia other than the presenting event; Systolic blood pressure more than 185 or
             diastolic blood pressure more than 110 mmHg, or aggressive management (intravenous
             pharmacotherapy) necessary to reduce blood pressure to these limits; Clinical history
             suggestive of subarachnoid haemorrhage even if no blood is evident on computerised
             tomography (CT) scan; High risk of haemorrhage, including major surgery, trauma or
             gastrointestinal or urinary tract haemorrhage within the previous 21 days; Arterial
             puncture at a non-compressible site within the previous 7 days; Prolonged
             cardiopulmonary resuscitation (&gt; 2 minutes) within the previous 14 days; Acute
             pericarditis and/or subacute bacterial endocarditis; acute pancreatitis; Severe
             hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension
             (oesophageal varices) and active hepatitis; Active peptic ulceration; Known history of
             haemorrhagic stroke; Known defect of clotting or platelet function (other than
             antiplatelet therapy); Hypo- or hyperglycaemia (blood glucose &lt;2 mmol/l or &gt;18 mmol/l)
             sufficient to account for neurological symptoms; Seizure at onset of symptoms unless
             brain imaging identifies positive evidence of significant brain ischaemia (eg early
             ischaemic change or hyperdense vessel on plain computerised tomography (CT) scan,
             computerised tomography angiography (CTA) scan confirmed arterial occlusion);
             Pregnancy (for women of child-bearing potential a negative pregnancy test will be
             required prior to randomisation); Inadequate haemostasis: Taking warfarin and
             international normalised ratio (INR) &gt;1.3, Taking a Direct Oral Anticoagulant
             (dabigatran, rivaroxaban, apixaban, edoxaban) unless known to be &gt;12 hours since last
             dose and with normal coagulation assays, Low molecular weight heparin (at doses other
             than prophylaxis of venous thromboembolism) administered within the preceding 48
             hours, Unfractionated heparin administered within the previous 48 hours and activated
             partial thromboplastin time (APTT) is prolonged.

          -  Acute endovascular treatment for stroke planned.

          -  Any major medical condition likely to limit survival to day 90.

          -  Unavailable for day 90 follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Muir, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alicia Murray, BSc, PhD</last_name>
    <email>Alicia.Murray@glasgow.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Murray</last_name>
      <email>alicia.murray@glasgow.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

